Key points from article :
Juvenescence, a leading longevity biotech company, has acquired Ro5 to enhance its AI-driven drug discovery capabilities. Ro5 brings advanced machine learning tools and a biomedical knowledge graph that could accelerate Juvenescence’s mission to develop treatments for age-related diseases. This acquisition also deepens Juvenescence’s collaboration with UAE-based health tech company M42, with plans to establish an AI-powered drug development hub in Abu Dhabi.
Ro5’s technology leverages neural networks to predict how drug molecules will behave, dramatically reducing the time and cost of pharmaceutical development. With more than 85 million biological data points and 400 million mapped relationships, Ro5’s platform enables novel insights into drug-target interactions and compound design. Its integration is expected to support Juvenescence’s clinical programs in cognitive health, metabolism, immunity, and cellular repair.
Executives from both companies emphasized the synergy of combining cutting-edge AI with real-world healthcare infrastructure. Richard Marshall, CEO of Juvenescence, said Ro5’s team and platform were a perfect complement to its goals, while Ro5’s CEO Charles Dazler Knuff highlighted the opportunity to create a life sciences ecosystem in Abu Dhabi focused on AI innovation and global health.
While artificial intelligence is rapidly transforming biotech, Juvenescence acknowledges that drug development remains a complex process requiring both digital tools and traditional clinical validation. The company aims to use this hybrid approach—combining AI insights with in vitro and in vivo research—to bring safer, more effective therapies to patients faster.
